• Utkarsh Kohli, Pratik Pandharipande, Mordechai Muszkat, Gbenga G Sofowora, Eitan A Friedman, Mika Scheinin, Alastair J J Wood, E Wesley Ely, Rachel F Tyndale, Leena Choi, C Michael Stein, and Daniel Kurnik.
• Departments of Medicine and Pharmacology, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA.
• Eur. J. Clin. Pharmacol. 2012 Jun 1;68(6):937-42.

PurposeThere is a large interindividual variability in dexmedetomidine dose requirements for sedation of patients in intensive care units (ICU). Cytochrome P450 2A6 (CYP2A6) mediates an important route of dexmedetomidine metabolism, and genetic variation in CYP2A6 affects the clearance of other substrate drugs. We examined whether CYP2A6 genotypes affect dexmedetomidine disposition.MethodsIn 43 critically ill ICU patients receiving dexmedetomidine infusions adjusted to achieve the desired level of sedation, we determined a median of five plasma dexmedetomidine concentrations each. Forty subjects were genotyped for five common CYP2A6 alleles and grouped into normal (n = 33), intermediate (n = 5), and slow metabolizers (n = 2).ResultsUsing a Bayesian hierarchical nonlinear mixture model, estimated dexmedetomidine clearance was 49.1 L/h (posterior mean; 95% credible interval 41.4-57.6 L/h). There were no significant differences in dexmedetomidine clearance among normal, intermediate, and slow CYP2A6 metabolizer groups.ConclusionGenetic variation in CYP2A6 does not appear to be an important determinant of dexmedetomidine clearance in ICU patients.

19 keywords...

hide…